FDA approves Johnson & Johnson’s nasal spray for depression …
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. …
FDA Approves Johnson & Johnson’s Nasal Spray for Adults
5 days ago · The U.S. Food and Drug Administration (FDA) has approved a nasal spray to be used alone in adults with depression that is difficult to treat. On Tuesday, the FDA cleared the …
FDA approves standalone use of J&J’s ketamine-derived ... - CNN
5 days ago · The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe …
FDA approves Spravato, first monotherapy nasal spray to treat
6 days ago · Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral …
FDA Approves Nasal Spray for Depression - Newsweek
4 days ago · The nasal spray, Spravato, has had its approval expanded to be used as a standalone treatment for depression. ... Neuroscience, Johnson & Johnson Innovative …
FDA Approves Johnson & Johnson Nasal Spray for Depression
6 days ago · The Food and Drug Administration (FDA) has approved a nasal spray developed by Johnson & Johnson for depression.. A Johnson & Johnson press release shared that …
FDA approves nasal spray drug to treat depression
5 days ago · Johnson & Johnson said the study demonstrated that Spravato significantly improved depressive symptoms compared to placebo, with 22.5% of patients achieving …
J&J ketamine-derived nasal spray approved to treat depression
5 days ago · Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral …
FDA allows standalone use of nasal spray antidepressant Spravato ...
5 days ago · In the first nine months of 2024, the drug generated sales of about $780 million for its maker, Johnson & Johnson. Spravato is intended to be administered under the direct …
Janssen Announces U.S. FDA Approval of SPRAVATO - Johnson & Johnson
Aug 3, 2020 · SPRAVATO ® is approved in the United States, in conjunction with an oral antidepressant, to treat adults with treatment-resistant depression (TRD) and depressive …
- Some results have been removed